Search Results - "Cosme, Karelia"
-
1
Preliminary safety assessment of CIGB-210, an investigational peptide for HIV infection
Published in Human & experimental toxicology (01-01-2022)“…Current human immunodeficiency virus treatments need to be periodically administered lifelong. In this study we assess the effect of repeated doses of an…”
Get full text
Journal Article -
2
Viremia and antibody response in green monkeys (Chlorocebus aethiops sabaeus) infected with dengue virus type 2: A potential model for vaccine testing
Published in Microbiology and immunology (01-04-2009)“…ABSTRACT The increasingly limited availability and high cost of the hitherto most commonly used monkey species in dengue vaccine research has augmented the…”
Get full text
Journal Article -
3
Antigenicity and Immunogenicity of a Synthetic Oligosaccharide-Protein Conjugate Vaccine against Haemophilus influenzae Type b
Published in Infection and Immunity (01-12-2004)“…Classifications Services IAI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text
Journal Article -
4
Vaccine CIGB 247 is potentially safe for use as a novel therapeutic vaccine against cancer in Chlorocebus aethiops monkeys
Published in International immunopharmacology (01-07-2017)“…CIGB 247 is a novel cancer therapeutic vaccine based on human vascular endothelial growth factor (VEGF) variant molecule as antigen, in combination with a…”
Get full text
Journal Article -
5
A Synthetic Conjugate Polysaccharide Vaccine against Haemophilus Influenzae Type B
Published in Science (American Association for the Advancement of Science) (23-07-2004)“…Glycoconjugate vaccines provide effective prophylaxis against bacterial infections. To date, however, no commercial vaccine has been available in which the key…”
Get full text
Journal Article -
6
Measurement of hematological and serum biochemical normal values of captive housed Chlorocebus aethiops sabaeus monkeys and correlation with the age
Published in Journal of medical primatology (01-02-2016)“…Background Some factors such as sex, age, and captivity conditions have a direct influence on the normal hematological and serum biochemical parameters of…”
Get full text
Journal Article -
7
Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac
Published in Frontiers in oncology (2019)“…Heberprovac is a GnRH based vaccine candidate containing 2.4 mg of the GnRHm1-TT peptide as the main active principle; 245 μg of the very small size…”
Get full text
Journal Article -
8
Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates
Published in Vaccine (05-01-2012)“…Highlights ► CIGB-247 is a cancer therapeutic, based on recombinant modified VEGF as antigen, in combination with powerful adjuvant VSSP. ► We extend the…”
Get full text
Journal Article -
9
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo
Published in Molecular and cellular biochemistry (01-09-2008)“…Protein Kinase CK2 is a serine-threonine kinase frequently deregulated in many human tumors. Here, we hypothesized that a peptide binder to the CK2…”
Get full text
Journal Article -
10
Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates
Published in Vaccine (26-04-2010)“…Abstract We have developed a cancer vaccine candidate (hereafter denominated CIGB-247), based on recombinant modified human vascular endothelial growth factor…”
Get full text
Journal Article -
11
Olive baboons: a non-human primate model for testing dengue virus type 2 replication
Published in International journal of infectious diseases (01-12-2013)“…Summary Objective This study evaluated the use of a non-human primate, the olive baboon ( Papio anubis ), as a model of dengue infection. Olive baboons closely…”
Get full text
Journal Article -
12
Establecimiento de un ensayo de potencia in vivo para el antígeno de superficie recombinante del virus de la Hepatitis B, en vacunas monovalentes y combinadas
Published in Vaccimonitor (01-09-2014)“…En este trabajo se presenta el establecimiento de un ensayo de potencia en ratones con el objetivo de demostrar el poder inmunogénico del antígeno de…”
Get full text
Journal Article -
13
Nepidermina: A new therapeutic alternative in the treatment of patients with diabetic foot safety preclinical evaluation
Published in Toxicology letters (05-10-2008)Get full text
Journal Article -
14
Establishment of an in vivo potency assay for the recombinant hepatit is B surface antigen in monovalent and combined vaccines
Published in Vaccimonitor (01-12-2014)“…In this paper the development of potency assay in animals (mice) was made, with the objective of demonstrating the immunogenic power of the recombinant…”
Get full text
Journal Article -
15
Non-clinical toxicological studies carried out of a new biomolecule with anti tumoural effect
Published in Toxicology letters (05-10-2008)Get full text
Journal Article -
16
Toxicology and biodistribution study of CIGB-230, a DNA vaccine against hepatitis C virus
Published in Human & experimental toxicology (01-08-2009)“…CIGB-230, a mixture of a DNA plasmid expressing hepatitis C virus (HCV) structural antigens and a HCV recombinant capsid protein, has demonstrated to elicit…”
Get more information
Journal Article -
17
Ratio of HCV structural antigens in protein-based vaccine formulations is critical for functional immune response induction
Published in Biotechnology and applied biochemistry (01-07-2010)“…HCV (hepatitis C virus) infection is among the leading causes of chronic liver disease, but currently there is no vaccine available. Data have accumulated…”
Get full text
Journal Article -
18
Safety evaluation of CIGB-500, therapeutic option in the treatment of Acute Myocardium Infarct
Published in Toxicology letters (05-10-2008)Get full text
Journal Article -
19
Safety demonstration of multivalent antibody fragment anti-CEA M3 as biomarker
Published in Toxicology letters (05-10-2008)Get full text
Journal Article -
20
Immunization with a recombinant fowlpox virus expressing a hepatitis C virus core-E I polyprotein variant, protects mice and African green monkeys (Chlorocebus aethiops sabaeus) against challenge with a surrogate vaccinia virus
Published in Biotechnology and applied biochemistry (2008)Get full text
Journal Article